(NYSE American: NNVC) Hits Monday's Radar With Bullish Technicals (5 Key Potential Catalysts)

A past champ is back in the spotlight.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: NNVC) Hits Monday's Radar With Bullish Technicals (5 Key Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* May 4th Greetings, Friend! In the face of rising measles outbreaks, a clinical-stage company is advancing a novel antiviral designed to stop vi-rus-es by targeting how they attach to human cells. Early studies suggest the therapy may shorten illness duration and reduce transmission, offering both treatment and preventative potential. With encouraging safety data already in humans and ongoing regulatory engagement, this approach could complement vaccines, especially for vulnerable populations who remain at risk. As global case counts climb, this platform is gaining attention for its potential to reshape outbreak response. That's why for Monday, May 4th, this past champ is back on our radar: NanoViricides, Inc. (NYSE American: NNVC). NanoViricides, Inc. is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known vi-rus-es. NanoViricides, Inc. (NYSE American: NNVC) is developing broad-spectrum nanoviricides to combat several diseases: NV-387 combats RSV, CV-19, Flu/Bird Flu and Sm-all-pox/Mon-key-pox; NV-HHV-1 combats Shingles and others in the Herpes Family; other Nanoviricides™ combat other diseases like Dengue, Rabies, and Ebola/Marburg. This versatility exploits a feature common to all pathogenic vi-rus-es. A New Era in Targeted Anti-Viral Therapeutics The nanoviricide® technology enables direct attacks at multiple points on a vi-rus particle. It is believed that such attacks would lead to the vi-rus particle becoming ineffective at infecting cells. Antibodies in contrast attack a vi-rus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the vi-rus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of the company's knowledge, that is capable of both (a) attacking extracellular vi-rus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the vi-rus, thereby enabling complete control of a vi-rus infection. The Company's anti-viral therapeutics, "nanoviricides™," are designed to appear to the vi-rus like the native host cell surface to which it binds. Since these binding sites for a given vi--rus do not change despite mutations and other changes in the vi-rus, the Company believes that their drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given vi-rus, provided the vi-rus-binding portion of the nanoviricide is engineered appropriately. Vi-rus-es would not be able to escape the nanoviricide by viral mutations since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Vi-rus escape by mutations is a major problem in the treatment of viral diseases using conventional drugs. Versatile Platform Technology A nanoviricide is created by chemically attaching a vi-rus-binding ligand, derived from the binding site of the vi-rus on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a vi-rus mutates. Tailor-made design and selection of (1) the vi-rus-binding ligand; and (2) the backbone "nanomicelle", separately, allows the Company to rapidly optimize drug candidates (a) against a number of vi-rus-es; (b) for desired pharmacokinetic characteristics (e.g. sustained effect); and (c) for different routes of administration. This versatility is unmatched in the Industry. Vi-rus-specific nanoviricides have been created against important vi-rus-es such as HIV, Influenza and Bird Flu by choosing highly vi-rus-specific ligands. Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known vi-rus-es. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg. This is similar to antibiotics such as penicillin against bacteria that exploit a feature common to all bacteria. Schematic of a Nanoviricide™ Highly Customizable, Tailorable Platform Technology No Encapsulated API in Current Generate of Nanoviricides Drug Candidates Provides Simplicity. NanoViricides Drugs Pipeline Grab Sources And More Here: NNVC Website. ----- Our Radar Is Pinging 5 Potential Catalysts For (NYSE American: NNVC) 1.) A Low Float Of This Size Could Create A Situation For Significant Volatility Potential. With roughly 19.63Mn shares in its float, volatility potential could become heightened at the drop of a hat for NNVC. 2.) Multiple Technical Indicators Are Appearing Triggered Right Now. Over at Barchart, the website is reporting that NNVC has several triggered technical indicators. As of close on Tuesday, there were a total of 7 with bullish signals across the short, medium, and long term. On top of that, the Barchart website's composite "Trend Seeker" indicator is flashing as well. 3.) Measles Rare Pediatric Disease Drug Designation Application Filed For NV-387, PRV Provides For Strong Business Case. NanoViricides advances NV-387 for measles by filing Rare Pediatric Disease Drug designation, strengthening regulatory and commercial prospects. Combined with its earlier orphan designation application, the effort could unlock a valuable Priority Review Voucher potentially worth around $160Mn. With no approved measles treatments and cases rising globally, NV-387 positions the company to address a significant unmet need. The designation pathway enhances development momentum, supports approval strategy, and reinforces NanoViricides’ innovative antiviral platform as both medically impactful and financially compelling for future growth. 4.) Phase II Clinical Trial Of Mon-key-pox Treatment by NV-387 To Commence Soon. NanoViricides moves toward a key milestone as its Phase II trial of NV-387 for MPox prepares to begin in the Democratic Republic of Congo. Regulatory clearance and site readiness signal strong execution capability and global collaboration. The study will assess safety and efficacy against the severe Clade I vi-rus, positioning NV-387 as a potentially critical treatment where none currently exists. Orphan Drug incentives could add meaningful financial benefits, while success may open large government stockpiling opp's, reinforcing NV-387 as a leading broad-spectrum antiviral candidate with significant medical and commercial promise. 5.) M-Pox Orphan Drug Designation Application Filed for NV-387. NanoViricides aims to enhance its M-Pox program by filing for Orphan Drug Designation for NV-387, strengthening both regulatory positioning and long-term market potential. The designation could provide tax credits, fee waivers, and seven years of exclusivity, improving development economics. With M-Pox evolving into a more transmissible global threat and no approved targeted treatments available, NV-387 offers a promising solution based on the company’s host-mimetic nanomedicine platform. Leadership emphasizes its potential as an important antiviral tool, reinforcing NanoViricides’ role in addressing emerging infectious diseases while building meaningful commercial value and future growth ahead. ----- Coverage is now kicked-off on NanoViricides, Inc. (NYSE American: NNVC). Updates will be circulating shortly. Keep your eyes peeled. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/04/2026 and ending on 05/04/2026 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty thousand USD ("Funds"). These Funds were part of the seven thousand five hundred USD funds that TD Media LLC received from a third party named Interactive Offers LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/nnvc-m24vn/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice